Close

Press Releases

Atreca Appoints Acclaimed Immunology Researcher Mark M. Davis, Ph.D., as a Technical Advisor

August 10, 2016

REDWOOD CITY, Calif. — Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today the appointment of Mark M. Davis, Ph.D., as a technical Advisor. Dr. Davis is a preeminent researcher who has greatly advanced knowledge of the human immune system during the course of his more than three-decade career at Stanford University School of Medicine.

“We are thrilled that Mark is joining our world-class team of advisors,” said William H. Robinson, M.D., Ph.D., Atreca Board member, Co-Founder, and Associate Professor of Medicine in the Division of Immunology and Rheumatology of the Department of Medicine at Stanford University. “His groundbreaking work has opened up new fields and provided the foundation for many advances in immunology. We look forward to his insights and contributions as Atreca continues to advance its programs.”

“Multiple key aspects of T-cell biology were discovered by Mark’s pioneering investigations,” said Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder. “Our collaboration with a scientist having such a deep understanding of T cell biology and immunology will greatly enhance Atreca’s efforts to harness the activity of the immune response to meet the needs of cancer patients.”

Dr. Davis is Director of the Stanford Institute for Immunity, Transplantation, and Infection at Stanford University School of Medicine, where he is the Avery Family Professor of Immunology in the Department of Microbiology and Immunology. Dr. Davis is also an Investigator of the Howard Hughes Medical Institute. Dr. Davis pioneered the identification and characterization of the T-cell receptor genes and T cell receptor binding to antigen/MHC complexes, including development of a novel way of identifying specific T lymphocytes (“peptide-MHC tetramers”), which is widely used in both clinical and basic immunology studies. Dr. Davis is the author or coauthor of more than 300 peer-reviewed articles and books, is a member of the National Academy of Sciences, and is the recipient of numerous awards and distinctions. Dr. Davis received his BA degree in molecular biology from The Johns Hopkins University and his PhD degree in molecular biology from the California Institute of Technology. He was a postdoctoral fellow at the Laboratory of Immunology at the National Institutes of Health prior to joining Stanford.

About Atreca, Inc.

Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. Atreca is able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture™ technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.

Contacts

Atreca, Inc.:
Susan Berland EVP and Chief Financial Officer
info@atreca.com

or

Media: Justin Jackson, 212-213-0006, ext. 327
jjackson@burnsmc.com